Literature DB >> 20554432

ApoE epsilon4 genotype and the age at onset of temporal lobe epilepsy: a case-control study and meta-analysis.

Marcelo Andrés Kauffman1, Damián Consalvo, Dolores Gonzalez Moron, Virginia Pujol Lereis, Silvia Kochen.   

Abstract

In order to investigate the role of ApoE epsilon4 as a modifier of the age at onset of temporal lobe epilepsy (TLE), we performed a molecular epidemiology study in 78 patients with mesial temporal lobe epilepsy and hippocampal sclerosis. Genotyping was done by a PCR-RFLP assay. In order to better estimate the role of this variant as a modifier of the age at onset, we also performed a systematic review of the literature. We included our results into a meta-analysis along with data available from seven published studies with 728 patients that looked into the role of ApoE epsilon4 in TLE. We found that ApoE epsilon4 carriers in our population had a non-significant earlier age of epilepsy onset than non-carriers. The meta-analysis confirmed this finding, showing that ApoE epsilon4 carriers had epilepsy onset almost 4 years earlier than non-carriers (mean difference 5.15 years; CI 95% 2.08-6.22; p=0.001). In conclusion, the ApoE epsilon4 isoform is a genetic factor that might influence the age at onset of TLE.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20554432     DOI: 10.1016/j.eplepsyres.2010.05.007

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  17 in total

1.  Activating PPARγ Increases NQO1 and γ-GCS Expression via Nrf2 in Thrombin-activated Microglia.

Authors:  Hang Hang; Li-Kun Wang; Si-Ying Ren; An-Jun Song; Guo-Feng Wu
Journal:  Curr Med Sci       Date:  2020-03-13

2.  Epilepsy and Alzheimer's Disease: Ubiquitous Entities Subject to the Same Cosmic Forces but on Different Astral Planes.

Authors:  Cynthia L Harden
Journal:  Epilepsy Curr       Date:  2018 Sep-Oct       Impact factor: 7.500

3.  Antisense reduction of tau in adult mice protects against seizures.

Authors:  Sarah L DeVos; Dustin K Goncharoff; Guo Chen; Carey S Kebodeaux; Kaoru Yamada; Floy R Stewart; Dorothy R Schuler; Susan E Maloney; David F Wozniak; Frank Rigo; C Frank Bennett; John R Cirrito; David M Holtzman; Timothy M Miller
Journal:  J Neurosci       Date:  2013-07-31       Impact factor: 6.167

4.  Apolipoprotein E polymorphisms and severity of cerebral palsy: a cross-sectional study in 255 children in Norway.

Authors:  Espen Lien; Guro L Andersen; Yongde Bao; Heather Gordish-Dressman; Jon S Skranes; Torstein Vik; James A Blackman
Journal:  Dev Med Child Neurol       Date:  2013-02-05       Impact factor: 5.449

5.  No association between ApoE polymorphism and febrile seizures.

Authors:  Pierre Lavenex; Pamela Banta Lavenex; François Cachat; Mario Gehri; Typhaine Juvet
Journal:  Neurol Sci       Date:  2015-08-02       Impact factor: 3.307

6.  Genetics of temporal lobe epilepsy: a review.

Authors:  Annick Salzmann; Alain Malafosse
Journal:  Epilepsy Res Treat       Date:  2012-02-19

7.  Evidence that an APOE ε4 'double whammy' increases risk for Alzheimer's disease.

Authors:  Ina Caesar; Sam Gandy
Journal:  BMC Med       Date:  2012-04-13       Impact factor: 8.775

8.  Apolipoprotein E gene polymorphism and the risk of intracerebral hemorrhage: a meta-analysis of epidemiologic studies.

Authors:  Rongjun Zhang; Xiaofeng Wang; Zongchun Tang; Jianxin Liu; Shuzhen Yang; Youbing Zhang; Yijun Wei; Wenyin Luo; Jun Wang; Jialong Li; Bobo Chen; Kunhu Zhang
Journal:  Lipids Health Dis       Date:  2014-03-12       Impact factor: 3.876

9.  A comparative study of the dentate gyrus in hippocampal sclerosis in epilepsy and dementia.

Authors:  R Bandopadhyay; J Y W Liu; S M Sisodiya; M Thom
Journal:  Neuropathol Appl Neurobiol       Date:  2014-02       Impact factor: 8.090

10.  Apolipoprotein E ε4 Allele was Associated With Nonlesional Mesial Temporal Lobe Epilepsy in Han Chinese Population.

Authors:  Zhimei Li; Chengyun Ding; Xiping Gong; Xiaofei Wang; Tao Cui
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.